- Home
- WK vs DNLI Comparison
WK vs DNLI Comparison
Compare WK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WK | DNLI |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WK | DNLI |
|---|---|---|
| Price | $48.50 | $20.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $95.30 | $34.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.53 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $884,568,000.00 | N/A |
| Revenue This Year | $20.85 | N/A |
| Revenue Next Year | $15.43 | $408.85 |
| P/E Ratio | $144.88 | ★ N/A |
| Revenue Growth | ★ 19.75 | N/A |
| 52 Week Low | $43.34 | $12.58 |
| 52 Week High | $97.10 | $23.77 |
Technical Indicators
Market Signals| Indicator | WK | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 56.63 |
| Support Level | $43.34 | $17.99 |
| Resistance Level | $52.50 | $20.65 |
| Average True Range (ATR) | 2.60 | 0.90 |
| MACD | 0.27 | 0.15 |
| Stochastic Oscillator | 52.81 | 89.79 |
Price Performance
Historical ComparisonAbout WK Workiva Inc.
Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.